← Leaderboards
Jay K Kolls
Tulane University Of Louisiana
$45,526,904
Attributed
$46,595,661
Total exposure
29
Grants
25
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$61,601,019 · 32
By mechanism
R01$20,099,790 · 7
P50$10,435,423 · 4
R35$7,403,277 · 2
U19$5,818,628 · 3
P01$4,352,634 · 4
P30$4,325,776 · 2
Top collaborators
- Marie A Krousel-Wood5 shared
- Raymond A Frizzell3 shared
- Mandy J Mcgeachy3 shared
- Larry W Moreland3 shared
- Joseph M Pilewski3 shared
- Simon C Watkins3 shared
- Richard Malley1 shared
- Gregory P Priebe1 shared
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungCytokineInfectionCellsResponseBaseMediatingT-LymphocyteImmunityCd4 Positive T LymphocytesPneumoniaFundingIn VitroProductionAntigensGenesIn VivoHost DefenseOrganismPreventMacrophageProteinsComplicationHiv Infections
Grant awards (160)
Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity (IMPACT-CETR)$4,776,780
U19 · FY2025 · AI
CD4+ T cell Immunity in the Respiratory Tract$1,063,324
R35 · FY2025 · HL · contact PI
Vaccines for Klebsiella$729,107
U19 · FY2025 · AI · contact PI
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia$468,554
R01 · FY2025 · AI · contact PI
Transgenic Mouse Core$312,741
U19 · FY2025 · AI · contact PI
Tulane StARR Program$252,469
R38 · FY2025 · HL
In vitro PCLS models of Pneumocystis$179,105
R21 · FY2025 · AI · contact PI
CD4_T-cell_Immunity_in_the_Lung$851,801
R35 · FY2024 · HL · contact PI
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia$474,108
R01 · FY2024 · AI · contact PI
Tulane StARR Program$253,049
R38 · FY2024 · HL
In vitro PCLS models of Pneumocystis$228,198
R21 · FY2024 · AI · contact PI
CD4_T-cell_Immunity_in_the_Lung$869,186
R35 · FY2023 · HL · contact PI
Immunotherapy of KPC Infection$486,421
R01 · FY2023 · AI · contact PI
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia$479,515
R01 · FY2023 · AI · contact PI
Tulane StARR Program$308,031
R38 · FY2023 · HL
CD4_T-cell_Immunity_in_the_Lung$869,186
R35 · FY2022 · HL · contact PI
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia$510,664
R01 · FY2022 · AI · contact PI
Immunotherapy of KPC Infection$486,421
R01 · FY2022 · AI · contact PI
Tulane StARR Program$308,031
R38 · FY2022 · HL
CD4_T-cell_Immunity_in_the_Lung$967,305
R35 · FY2021 · HL · contact PI
Immunotherapy of KPC Infection$486,421
R01 · FY2021 · AI · contact PI
Tulane StARR Program$162,891
R38 · FY2021 · HL
CD4_T-cell_Immunity_in_the_Lung$964,052
R35 · FY2020 · HL · contact PI
Immunotherapy of KPC Infection$486,421
R01 · FY2020 · AI · contact PI
Improved Therapeutics and Diagnostics for PneumocystisPneumonia$448,285
R01 · FY2020 · AI · contact PI
CD4_T-cell_Immunity_in_the_Lung$864,156
R35 · FY2019 · HL · contact PI
Improved Therapeutics and Diagnostics for PneumocystisPneumonia$457,733
R01 · FY2019 · AI · contact PI
Core C RNA Sequencing and Bioinformatics$251,962
P01 · FY2019 · AI · contact PI
Training in CD4 T-cell Lung Immunity$93,728
R35 · FY2019 · HL · contact PI
CD4_T-cell_Immunity_in_the_Lung$860,539
R35 · FY2018 · HL · contact PI
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia$479,335
R01 · FY2018 · AI · contact PI
Core C RNA Sequencing and Bioinformatics$252,787
P01 · FY2018 · AI · contact PI
Basic and Translational Studies of Cystic Fibrosis$1,038,005
P30 · FY2017 · DK
Core C RNA Sequencing and Bioinformatics$264,317
P01 · FY2017 · AI · contact PI
Th17 Cytokines and Lung Immunity$263,948
R37 · FY2017 · HL · contact PI
T-Cells and P. Carinii Pneumonia$261,762
R01 · FY2017 · HL · contact PI
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia$248,708
R01 · FY2017 · AI · contact PI
Improved Therapeutics and Diagnostics for PneumocystisPneumonia$245,040
R01 · FY2017 · AI · contact PI
Th17 Cytokines and Lung Immunity$172,881
R37 · FY2017 · HL · contact PI
T-Cells and P. Carinii Pneumonia$162,478
R01 · FY2017 · HL · contact PI
Generation of Novel Human Monoclonals for Lung Disease$161,083
R21 · FY2017 · AI · contact PI
Generation of Novel Human Monoclonals for Lung Disease$67,859
R21 · FY2017 · AI · contact PI
Basic and Translational Studies of Cystic Fibrosis$1,049,630
P30 · FY2016 · DK
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia$487,618
R01 · FY2016 · AI · contact PI
Th17 Cytokines and Lung Immunity$440,851
R37 · FY2016 · HL · contact PI
T-Cells and P. Carinii Pneumonia$428,693
R01 · FY2016 · HL · contact PI
Core C RNA Sequencing and Bioinformatics$266,171
P01 · FY2016 · AI · contact PI
UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)$251,859
UH2 · FY2016 · AR
Generation of Novel Human Monoclonals for Lung Disease$192,500
R21 · FY2016 · AI · contact PI
UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)$137,922
UH2 · FY2016 · AR
Basic and Translational Studies of Cystic Fibrosis$1,060,473
P30 · FY2015 · DK
Th17 Cytokines and Lung Immunity$440,851
R37 · FY2015 · HL · contact PI
CD4-Dependent vaccination against pneumocystis$374,381
P01 · FY2015 · HL · contact PI
Core C RNA Sequencing and Bioinformatics$275,783
P01 · FY2015 · AI · contact PI
UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)$250,001
UH2 · FY2015 · AR
Th17 Cytokines and Lung Immunity$86,240
R37 · FY2015 · HL · contact PI
Th17 Cytokines and Lung Immunity$507,666
R37 · FY2014 · HL · contact PI
T cells and P carinii Pneumonia$390,160
R01 · FY2014 · HL · contact PI
CD4-Dependent vaccination against pneumocystis$368,852
P01 · FY2014 · HL · contact PI
Pittsburgh Pediatric Rheumatology Training Grant$197,205
T32 · FY2014 · AR · contact PI
Research Component 3$124,571
P60 · FY2014 · AA · contact PI
Th17 Cytokines and Lung Immunity$415,740
R37 · FY2013 · HL · contact PI
T cells and P carinii Pneumonia$375,633
R01 · FY2013 · HL · contact PI
Non-CD4 Host Defense Against P. Carinii Pneumonia$360,570
R01 · FY2013 · HL · contact PI
CD4-Dependent vaccination against pneumocystis$358,314
P01 · FY2013 · HL · contact PI
Pittsburgh Pediatric Rheumatology Training Grant$178,358
T32 · FY2013 · AR · contact PI
Research Component 3$115,028
P60 · FY2013 · AA · contact PI
Th17 Cytokines and Lung Immunity$64,421
R37 · FY2013 · HL · contact PI
Th17 Cytokines and Lung Immunity$441,029
R37 · FY2012 · HL · contact PI
T cells and P carinii Pneumonia$390,779
R01 · FY2012 · HL · contact PI
Non-CD4 Host Defense Against P. Carinii Pneumonia$378,750
R01 · FY2012 · HL · contact PI
CD4-Dependent vaccination against pneumocystis$376,379
P01 · FY2012 · HL · contact PI
Novel Macrolide Th17 Inhibitors$217,372
R21 · FY2012 · HL · contact PI
Pittsburgh Pediatric Rheumatology Training Grant$156,295
T32 · FY2012 · AR · contact PI
Research Component 3$114,615
P60 · FY2012 · AA · contact PI
Th17 Cytokines and Lung Immunity$399,553
R37 · FY2011 · HL · contact PI
T cells and P carinii Pneumonia$312,400
R01 · FY2011 · HL · contact PI
Non-CD4 Host Defense Against P. Carinii Pneumonia$184,600
R01 · FY2011 · HL · contact PI
Non-CD4 Host Defense Against P. Carinii Pneumonia$170,400
R01 · FY2011 · HL · contact PI
Novel Macrolide Th17 Inhibitors$104,881
R21 · FY2011 · HL · contact PI
Research Component 3$91,858
P60 · FY2011 · AA · contact PI
Novel Macrolide Th17 Inhibitors$78,934
R21 · FY2011 · HL · contact PI
T cells and P carinii Pneumonia$49,517
R01 · FY2011 · HL · contact PI
Immune Tolerance and Inflammation in ABPA in Patients with Cystic Fibrosis$516,023
P50 · FY2010 · HL · contact PI
Th17 Cytokines and Lung Immunity$414,288
R37 · FY2010 · HL · contact PI
Alcohol, ROS, and Macrophage Epigenetics$381,752
R01 · FY2010 · AA · contact PI
Non-CD4 Host Defense Against P. Carinii Pneumonia$355,000
R01 · FY2010 · HL · contact PI
T cells and P carinii Pneumonia$351,450
R01 · FY2010 · HL · contact PI
Research Component 3$126,534
P60 · FY2010 · AA · contact PI
Alcohol, ROS, and Macrophage Epigenetics$50,938
R01 · FY2010 · AA · contact PI
Alcohol, ROS, and Macrophage Epigenetics$24,518
R01 · FY2010 · AA · contact PI
2010 Biology of Acute Respiratory Infection Gordon Research Conference$15,000
R13 · FY2010 · AI · contact PI
Immune Tolerance and Inflammation in ABPA in Patients with Cystic Fibrosis$501,914
P50 · FY2009 · HL · contact PI
IL-23 / Il-17 and Lung Host Defense$392,390
R01 · FY2009 · HL · contact PI
Non-CD4 Host Defense Against P. Carinii Pneumonia$355,000
R01 · FY2009 · HL · contact PI
Alcohol, ROS, and Macrophage Epigenetics$289,552
R01 · FY2009 · AA · contact PI
CORE--CLINICAL STUDIES AND OUTCOMES$274,341
P30 · FY2009 · DK · contact PI
Alcohol, ROS, and Macrophage Epigenetics$124,842
R01 · FY2009 · AA · contact PI
Alcohol, ROS, and Macrophage Epigenetics$9,727
R01 · FY2009 · AA · contact PI
IL-23 / Il-17 and Lung Host Defense$7,690
R01 · FY2009 · HL · contact PI
CD8 T-Cells and Host Defense Against P. Carinii$7,690
R01 · FY2009 · HL · contact PI
Host Factors in Fungal Allergy and Fibrosis$2,391,911
P50 · FY2008 · HL · contact PI
Immune Tolerance and Inflammation in ABPA in Patients with Cystic Fibrosis$386,146
P50 · FY2008 · HL · contact PI
IL-23 / Il-17 and Lung Host Defense$379,418
R01 · FY2008 · HL · contact PI
CD4-Independent Vaccinations for Pulmonary Infections$367,184
P01 · FY2008 · HL · contact PI
Core--Molecular/Cellular Biology Laboratory Core$276,058
P60 · FY2008 · AA · contact PI
CORE--CLINICAL STUDIES AND OUTCOMES$274,341
P30 · FY2008 · DK · contact PI
Alcohol, ROS, and Macrophage Epigenetics$233,265
R01 · FY2008 · AA · contact PI
CD8 T-Cells and Host Defense Against P. Carinii$227,085
R01 · FY2008 · HL · contact PI
CD8 T-Cells and Host Defense Against P. Carinii$88,203
R01 · FY2008 · HL · contact PI
Alcohol, ROS, and Macrophage Epigenetics$59,346
R01 · FY2008 · AA · contact PI
Host Factors in Fungal Allergy and Fibrosis$2,373,870
P50 · FY2007 · HL · contact PI
CD4-Independent Vaccinations for Pulmonary Infections$860,610
P01 · FY2007 · HL · contact PI
Immune Tolerance and Inflammation in ABPA in Patients with Cystic Fibrosis$525,141
P50 · FY2007 · HL · contact PI
IL-23 / Il-17 and Lung Host Defense$378,697
R01 · FY2007 · HL · contact PI
CD8 T-Cells and Host Defense Against P. Carinii$315,288
R01 · FY2007 · HL · contact PI
Alcohol, ROS, and Macrophage Epigenetics$292,611
R01 · FY2007 · AA · contact PI
Non-CD4 Host defense against P. carinii Pneumonia$289,118
R01 · FY2007 · HL · contact PI
Core--Molecular/Cellular Biology Laboratory Core$267,747
P60 · FY2007 · AA · contact PI
CORE--CLINICAL STUDIES AND OUTCOMES$202,597
P30 · FY2007 · DK · contact PI
Host Factors in Fungal Allergy and Fibrosis$2,314,689
P50 · FY2006 · HL · contact PI
Immune Tolerance and Inflammation in ABPA in Patients with Cystic Fibrosis$480,346
P50 · FY2006 · HL · contact PI
IL-23 / Il-17 and Lung Host Defense$381,422
R01 · FY2006 · HL · contact PI
CD8 T-Cells and Host Defense Against P. Carinii$315,288
R01 · FY2006 · HL · contact PI
Non-CD4 Host defense against P. carinii Pneumonia$308,373
R01 · FY2006 · HL · contact PI
Alcohol, ROS, and Macrophage Epigenetics$301,350
R01 · FY2006 · AA · contact PI
CORE--MOLECULAR/CELLULAR BIOLOGY LABORATORY CORE$233,523
P60 · FY2006 · AA · contact PI
CORE--CLINICAL STUDIES AND OUTCOMES$202,132
P30 · FY2006 · DK · contact PI
Administrative Core$117,016
P50 · FY2006 · HL · contact PI
IL-23 / Il-17 and Lung Host Defense$391,865
R01 · FY2005 · HL
CD8 T-Cells and Host Defense Against P. Carinii$322,875
R01 · FY2005 · HL
Non-CD4 Host defense against P. carinii Pneumonia$322,875
R01 · FY2005 · HL
ALCOHOL, IMMUNOSUPPRESSION, AND TACE$287,000
R01 · FY2005 · AA
CORE--MOLECULAR/CELLULAR BIOLOGY LABORATORY CORE$233,523
P60 · FY2005 · AA
CORE--CLINICAL STUDIES AND OUTCOMES$224,257
P30 · FY2005 · DK
CD8 T-Cells and Host Defense Against P. Carinii$358,750
R01 · FY2004 · HL
CD4-Independent Vaccinations for Pulmonary Infections$335,894
P01 · FY2004 · HL
Non-CD4 Host defense against P. carinii Pneumonia$322,313
R01 · FY2004 · HL
ALCOHOL, IMMUNOSUPPRESSION, AND TACE$286,667
R01 · FY2004 · AA
CORE--MOLECULAR/CELLULAR BIOLOGY LABORATORY CORE$233,523
P60 · FY2004 · AA
Non-CD4 Host defense against P. carinii Pneumonia$319,500
R01 · FY2003 · HL
ALCOHOL, IMMUNOSUPPRESSION, AND TACE$205,900
R01 · FY2003 · AA
ALCOHOL, IMMUNOSUPPRESSION, AND TACE$80,100
R01 · FY2003 · AA
ALCOHOL, IMMUNOSUPPRESSION, AND TACE$286,000
R01 · FY2002 · AA
CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA$180,706
R01 · FY2002 · HL
CORE--LABORATORY$130,719
P50 · FY2002 · AA
CORE--LABORATORY$130,719
P50 · FY2002 · AA
NON CD4 HOST DEFENSE AGAINST P CARINII PNEUMONIA$78,314
R01 · FY2002 · HL
CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA$74,520
R01 · FY2002 · HL
ALCOHOL, IMMUNOSUPPRESSION, AND TACE$286,000
R01 · FY2001 · AA
CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA$255,226
R01 · FY2001 · HL
CORE--LABORATORY$184,557
P50 · FY2001 · AA
NON CD4 HOST DEFENSE AGAINST P CARINII PNEUMONIA$76,076
R01 · FY2001 · HL
CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA$4,976
R01 · FY2001 · HL
CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA$4,976
R01 · FY2001 · HL
CORE--LABORATORY$0
P50 · FY2001 · AA
CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA$250,250
R01 · FY2000 · HL
CORE--LABORATORY$197,815
P50 · FY2000 · AA
CORE--LABORATORY$184,557
P50 · FY2000 · AA
NON CD4 HOST DEFENSE AGAINST P CARINII PNEUMONIA$73,902
R01 · FY2000 · HL